Certara Reports Third Quarter 2024 Financial Results
Updates Full Year 2024 Financial Guidance RADNOR, PA — November 6, 2024-- Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT),…
Danielle Pillsbury2024年11月6日
How Modeling Was Used to Support the FDA Approval of a Topical Generic Drug Product
Establishing bioequivalence for topical drug products can be challenging and costly, often requiring extensive comparative…
Certara2024年11月5日
Informing pregnancy dose via target-mediated drug disposition modeling and simulations for a recombinant human monoclonal antibody
The article titled "Informing pregnancy dose via target-mediated drug disposition modeling and simulations for a…
Danielle Pillsbury2024年11月4日
FAQs on Developing EMA Policy 0070 Submissions
In September 2023, the European Medicines Agency (EMA) reinstated its Policy 0070 requirement to publish…
Certara2024年11月1日
Improved Translation of Clinical TCE Dosing with Mechanistic Modeling
要旨：Regulatory agencies recommend quantitative justifications for clinical dose selection. T-cell engagers (TCE) pose particular…
Renee Fisher2024年10月31日
Applications of a QSP Model of LNP mRNA Delivery for the Treatment of Crigler-Najjar Syndrome Type 1
Applications of a QSP Model of LNP mRNA Delivery for the Treatment of Crigler-Najjar Syndrome Type 1
要旨：Crigler-Najjar syndrome type 1 (CN1) is an autosomal recessive disease caused by a marked…
Renee Fisher2024年10月31日
Guiding Target and Lead Optimization for a Molecular Glue Degrader
Learn how to optimize drug properties for protein degrader therapeutics by exploring system characteristics.
Renee Fisher2024年10月31日
